UK Markets close in 3 hrs 28 mins
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • FTSE 250

    23,574.62
    +140.55 (+0.60%)
     
  • AIM

    1,236.75
    -10.13 (-0.81%)
     
  • GBP/EUR

    1.1873
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • BTC-GBP

    42,755.21
    +1,751.38 (+4.27%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • DOW

    35,870.95
    -60.10 (-0.17%)
     
  • GOLD FUTURES

    1,861.20
    -0.20 (-0.01%)
     
  • NIKKEI 225

    29,683.09
    +84.43 (+0.29%)
     
  • HANG SENG

    25,319.72
    -330.36 (-1.29%)
     
  • DAX

    16,221.73
    -29.40 (-0.18%)
     
  • CAC 40

    7,141.98
    -14.87 (-0.21%)
     

Global Assisted Reproductive Technology Market (2021 to 2030) - Opportunity Analysis and Industry Forecasts

·10-min read

Dublin, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Market by Product, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global assisted reproductive technology market was valued at $2,317.7 million in 2020, and is estimated to reach $12,272.5 million by 2030, growing at a CAGR of 19.3% from 2021 to 2030.

Assisted reproductive technology (ART) is defined as the medical procedure used to address the infertility treatments for handling of eggs and embryo. This technique aims to remove the eggs from a woman's ovaries and further combine it with sperm in the in-vitro laboratory condition. After fertilization, the egg or embryo is transferred to the uterus of women. It alleviates the burden of infertility on a family and individual. In-vitro technology is one of the most common and advanced procedures, which are used for the infertility treatment. The ART includes gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), zygote intrafallopian transfer and in vitro fertilization-embryo transfer.

The global assisted reproductive technology market is majorly driven by an alarming increase in the prevalence of polycystic ovary syndrome, rise in disposable income, surge in demand for in vitro-fertilization, advancement in the technology for novel ART, and a rise in awareness about IVF and surrogacy. According to Office on Women's Health (OASH), in 2019, it was reported that 1 in 10 women of childbearing age are diagnosed with PCOS, in the U.S. According to Center for Disease control and Prevention (CDC), it was reported that 6% to 12% of the U.S. women of reproductive age, having PCOS, were also diagnosed with infertility.

PCOS is one of the most common causes of female infertility, which surge the demand for assisted reproductive technology and drive the growth of the market. The rise in disposable income has assisted reproductive technology and drives the growth of the market. Furthermore, in February 2021, TMRW Life Sciences, announced the launch of the world's first automated Cryo specimen management solution for eggs and embryo, which are used in the IVF procedure. The TMRW platform is introduced in various fertility clinics in the U.S. launching the software enables management of the million embryos and eggs central to modern IVF.

Increase in incidence of infertility cases and the surge in sedentary lifestyle are the major factors that drive the global assisted reproductive technology market. Moreover, the increase in prevalence of obesity significantly contributes toward the market growth, owing to obese person being more prone to infertility and uterine disorder. Rise in demand for in-vitro fertilization for effective treatment, and high success rate acts a key driving force of the global market.

Furthermore, governments are taking multiple initiatives to support healthcare information systems for development of advanced ART, which is expected to boost the market growth. As per a study by the American Society for reproductive medicines, it was reported that approximately 40% of infertile couple, the male partner is responsible for infertility and among them 85% to 90% are treated with surgery. In addition, technological advancements in assisted reproductive technology, and growth in number of fertility clinic are anticipated to provide lucrative opportunities for the market expansion. The rise in awareness regarding cost-effective treatment of infertility and spread of knowledge about the success rate of IVF procedure propels the growth of the market.

On the contrary, risk associated after IVF procedure and high cost of assisted reproductive technology are anticipated to hinder the market growth during the forecast period. The rise in number of fertility clinic and development of IVD devices leads to the enhancement of the assisted reproductive technology sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the assisted reproductive technology market.

The global assisted reproductive technology market is segmented into product, technology, end user, and region. By product, the market is categorized into instrument, accessory & disposable, and reagent & media.

Key Benefits

  • The report provides an in-depth analysis of the global assisted reproductive technology market size along with the current trends and future estimations to elucidate the imminent investment pockets.

  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.

  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global assisted reproductive technology market.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter's five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of infertility rate
3.5.1.2. Technological advancements in assisted reproductive technology
3.5.1.3. Growth in disposable income and rise in awareness regarding infertility treatment
3.5.2. Restraint
3.5.2.1. High cost of ART procedure
3.5.2.2. Risk associated with IVF treatment
3.5.3. Opportunity
3.5.3.1. Growing opportunities in emerging market and rise in fertility tourism
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the assisted reproductive technology market

CHAPTER 4: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instrument
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Instrument, by type
4.2.2.1. Market size and forecast
4.2.2.2. Sperm separation system
4.2.2.2.1. Market size and forecast
4.2.2.3. Cryosystem
4.2.2.3.1. Market size and forecast
4.2.2.4. Incubator
4.2.2.4.1. Market size and forecast
4.2.2.5. Imaging system
4.2.2.5.1. Market size and forecast
4.2.2.6. Ovum aspiration pump
4.2.2.6.1. Market size and forecast
4.2.2.7. Cabinet
4.2.2.7.1. Market size and forecast
4.2.2.8. Micromanipulator
4.2.2.8.1. Market size and forecast
4.2.2.9. Laser systems
4.2.2.9.1. Market size and forecast
4.2.2.10. Others
4.2.2.10.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Accessory & Disposable
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Reagent & Media
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Reagent & Media, by type
4.4.2.1. Market size and forecast
4.4.2.2. Cryopreservation Media
4.4.2.2.1. Market size and forecast
4.4.2.3. Semen processing media
4.4.2.3.1. Market size and forecast
4.4.2.4. Ovum processing media
4.4.2.4.1. Market size and forecast
4.4.2.5. Embryo culture media
4.4.2.5.1. Market size and forecast
4.4.3. Market size and forecast, by region
4.4.4. Market analysis, by country

CHAPTER 5: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. In vitro-fertilization
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Artificial Insemination
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country
5.4. Others
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market analysis, by country

CHAPTER 6: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Fertility clinics
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. Hospital
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
6.4. Surgical center
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market analysis, by country
6.5. Clinical research institute
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market analysis, by country

CHAPTER 7: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES
8.1. COOK GROUP
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Key strategic moves and developments
8.2. FUJIFILM HOLDINGS CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GENEA BIOMEDX
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments
8.4. MERCK KGAA
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. INCEPTION SCIENCES, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. OXFORD GENE TECHNOLOGY IP LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. PROGYNY INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. THE COOPER COMPANIES, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. THERMO FISHER SCIENTIFIC, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. VITROLIFE AB
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

For more information about this report visit https://www.researchandmarkets.com/r/wk8ro1

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting